| Anxiety symptoms not worsened by COVID-19 pandemic (n = 16) | Anxiety symptoms worsened by COVID-19 pandemic (n = 86) | P value |
Male | 4 (25.0%) | 19 (21.1%) | 0.754 |
Female | 12 (75.0%) | 67 (77.9%) |
|
Compared with Pre-COVID-19 |
|
|
|
GAD-7 same or decrease | 11 (68.8%) | 49 (57%) | 0.547 |
GAD-7 increase | 5 (31.3%) | 37 (43%) |
|
PHQ-9 same or decrease | 12 (75.0%) | 49 (57%) | 0.283 |
PHQ-9 increase | 4 (25.0%) | 37 (43%) |
|
Medications |
|
| 0.757 |
Same dosage | 13 (81.3%) | 65 (75.6%) |
|
Step up or add new medications | 3 (18.8%) | 21 (24.4%) |
|
Social distancing |
|
| 0.006 |
Absent | 3 (18.8%) | 5 (5.8%) |
|
Mild | 7 (43.8%) | 16 (18.6%) |
|
Moderate | 4 (25.0%) | 38 (44.2%) |
|
Severe | 2 (12.5%) | 27 (31.4%) |
|
Financial impact |
|
|
|
Decreased income/unemployed | 2 (12.5%) | 16 (18.6%) | 0.731 |
Not affected | 14 (87.5%) | 70 (81.4%) |
|
Family relationship |
|
| 0.913 |
Worsen | 4 (25.0%) | 27 (31.4%) |
|
Not affected | 11 (68.8%) | 51 (59.3%) |
|
Improved | 1 (3.0%) | 8 (9.3%) |
|
| Mean (SD) | Mean (SD) |
|
GAD-7 (Pre-COVID-19) | 4.5 (3.97) | 4.92 (2.92) | 0.692 |
PHQ-9 (Pre-COVID-19) | 4 (3.54) | 3.45 (2.42) | 0.560 |
GAD-7 (Peri-COVID-19) | 3.13 (2.71) | 4.85 (3.04) | 0.037 |
PHQ-9 (Peri-COVID-19) | 2.81 (2.79) | 3.52 (2.35) | 0.283 |
|
|
|
|
Anxiety worsen by COVID-19 | Mean GAD-7 (Pre-COVID-19) 4.92 | Mean GAD-7 (Pre-COVID-19) 4.85 | 0.801 |
| Mean PHQ-9 (Pre-COVID-19) 3.45 | Mean PHQ-9 (Pre-COVID-19) 3.52 | 0.796 |